Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.
Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.
Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.
Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.
SciSparc (Nasdaq: SPRC) has announced a significant development in its collaboration with Clearmind Medicine Inc. Clearmind has published a patent application for innovative combinations of ketamine and N-acylethanolamines. This collaboration focuses on researching combination treatments using SciSparc's Palmitoylethanolamide (PEA) and Clearmind's psychedelic molecule, MEAI, for treating addictions, weight loss, and mental health disorders.
The partnership has already resulted in thirteen patent applications filed with the U.S. Patent and Trademark Office and other global patent offices. SciSparc's approach aims to reduce the number of doses of active ingredients while maintaining effectiveness and minimizing side effects, potentially improving treatment outcomes for various medical conditions.
SciSparc (Nasdaq: SPRC) has finalized an Exclusive Patent License Agreement with Polyrizon for the out-licensing of its SCI-160 program for pain treatment. The deal is worth up to $6 million, including:
- $3 million in Polyrizon securities
- Potential milestone fees of approximately $3 million in cash
- Royalties
SCI-160 is a synthetic combination of cannabinoids and N-acylethanolamines that has shown promising results in pre-clinical studies, demonstrating analgesic effects comparable to high-dose morphine without significant side effects. This development could potentially address the public health issue of opioid abuse in pain management.
SciSparc (Nasdaq: SPRC) has submitted an Investigational New Drug (IND) application to the FDA for its phase IIb clinical trial of SCI-110, a potential treatment for Tourette Syndrome (TS). The trial will be conducted at three leading centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. SCI-110, composed of dronabinol and palmitoylethanolamide, aims to address challenges in current TS treatments.
The study will evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65. Participants will be randomized to receive either SCI-110 or a placebo. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. The trial's primary safety objective is to assess the frequency of serious adverse events.
SciSparc (Nasdaq: SPRC) announced that MitoCareX Bio , its joint venture focusing on cancer drug discovery, has appointed Professor Nir Peled to its scientific advisory board. Prof. Peled, Director of Oncology at Shaare Zedek Medical Center and chair of the IASLC's Global Multidisciplinary Practice Standards Committee, brings extensive expertise in thoracic oncology. His research focuses on personalized targeted therapy, immunotherapy, and biomarker development for lung cancer.
This appointment follows MitoCareX's recent validation of its target SLC25 carrier protein in Non-Small Cell Lung Cancer cells. The company has identified potential anti-cancer treatments using its proprietary MITOLINE™ algorithm and advanced drug discovery platform.
SciSparc (Nasdaq: SPRC) has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, an innovative treatment for autism spectrum disorder (ASD). The trial, conducted at the Soroka Medical Center in Israel, is a double-blind, randomized, and placebo-controlled study involving 60 subjects aged 5-18 over 20 weeks. SCI-210 combines cannabidiol (CBD) with SciSparc's novel CannAmide™ formulation.
The study aims to compare SCI-210 therapy with standard CBD monotherapy in managing ASD symptoms. Primary efficacy metrics include the ABC-C parent questionnaire, CGI-I clinician assessment, and effective therapeutic dose. Following the trial, SciSparc plans to commercialize SCI-210 in Israel and potentially other countries, subject to regulatory approvals.
SciSparc (Nasdaq: SPRC) has signed an Exclusive Patent License Agreement with Polyrizon for the out-licensing of its SCI-160 program for pain treatment. The deal is valued at $3 million in Polyrizon securities, with potential additional milestone fees of $3 million in cash and royalties. SCI-160 is a proprietary synthetic combination of cannabinoids and N-acylethanolamines that has shown promising results in pre-clinical studies, demonstrating analgesic effects comparable to high-dose morphine without significant side effects. This agreement allows SciSparc to potentially benefit from the program's development without further investment, addressing the need for effective pain treatments amid the opioid abuse crisis.
SciSparc (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company, has provided an update on its merger agreement with AutoMax Motors The Jerusalem District Court in Israel has approved AutoMax's petition to convene special class meetings of its shareholders to approve the merger with SciSparc. This approval is a important step forward in the merger process.
Additionally, SciSparc has entered into an addendum to the Merger Agreement, extending the right to terminate the agreement if the merger is not consummated. The new deadline has been deferred from August 30, 2024, to November 30, 2024, providing more time for the merger to be completed.
SciSparc (Nasdaq: SPRC) has announced promising results from a study on 5-methoxy-2-aminoindane (MEAI), conducted in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The study, published in ACS Pharmacology and Translational Science, demonstrates MEAI's potential as a novel weight loss drug. Key findings include:
- Significant weight loss in diet-induced obese mice
- Improved glucose metabolism and increased energy expenditure
- Decreased fatty liver and reduced fat accumulation
- Well-tolerated combination treatment with elevated metabolic processes
This research is part of SciSparc and Clearmind's ongoing collaboration since 2022, focusing on developing innovative treatments for addictions, obesity, and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI.
SciSparc (Nasdaq: SPRC) announced that its venture, MitoCareX Bio , has validated the potential significant involvement of its target SLC25 carrier protein in Non-Small Cell Lung Cancer (NSCLC) cells. The discovery was demonstrated using genetic manipulations and 3D spheroid systems, mimicking human solid tumors. NSCLC, accounting for 80%-85% of all lung cancer cases globally, is projected to reach a market value of $59.77 billion by 2030.
MitoCareX previously screened millions of small molecules using its proprietary MITOLINE™ algorithm, identifying potential anti-cancer treatments. The company is now working on creating a predictive AI model to more efficiently discover novel anti-cancer small molecule scaffolds targeting its SLC25 protein of interest.
SciSparc (Nasdaq: SPRC) has signed a non-binding letter of intent (LOI) for the exclusive global out-licensing of its SCI-160 pain treatment program. The deal, valued at approximately $6 million, includes:
1. $3 million in ordinary shares and pre-funded warrants of the undisclosed biotechnology company
2. Potential additional payments and execution fees of about $3 million in cash, subject to meeting certain milestones
SCI-160 is a proprietary synthetic cannabinoid formulation that has shown promising results in pre-clinical studies, demonstrating analgesic effects comparable to high-dose morphine without significant side effects. This development aligns with efforts to address the opioid crisis, as prescription opioid-related deaths have increased significantly since 1999.
